Novo Nordisk AS (FRA:NOV) FFO


FRA:NOV Novo Nordisk AS FRA:NOV
81 GF Score
Price €42.25
GF Value €120.44
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Novo Nordisk AS FFO?

FFO (Funds from operations) only applies to REITs.

FRA:NOV
81GF Score
Novo Nordisk AS FRA:NOV
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Novo Nordisk AS (FRA:NOV) Overvalued in 2026?

Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued. The current stock price of €42.25 is trading 64.9% below its estimated GF Value™ of €120.44. GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.

Key valuation signals for FRA:NOV:

  • FFO:
  • GF Value™: €120.44 vs. price of €42.25 (64.9% below fair value)
  • GF Score™: 81/100 with 4 warning signs

No single metric tells the full story. See the FRA:NOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Novo Nordisk AS Business Description

Address Novo Alle 1, Bagsvaerd, DNK, 2880
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
81GF Score

Get the complete analysis for FRA:NOV

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€42.25
Price
€120.44
GF Value